Objective: To observe the effect and the incidence of adverse events of drug treatment and interventional treatment of aortic arch Myla classification for patients with ischemic cerebrovascular disease. Methods: A total of 120 patients with ischemic cerebrovascular disease in Bayannur City Hospital from 2018 to 2021 were selected as the research objects. According to different treatment methods, they were divided into drug group and surgical group. The drug group was treated with traditional drugs; on the basis of the classification of aortic arch, the patients in the surgical group were treated with corresponding surgical methods according to different aortic arches. The degree of vascular stenosis, operation time and incidence of adverse events were observed in the two groups. Results: (1)One vessel stenosis accounted for 55.0% in the drug group and 53.3% in the surgical group. Patients in both groups were mainly with one vessel stenosis, and there was no significant difference in the number of vascular stenosis between the two groups; (2)The surgical time of patients with more than two vascular lesions was longer than that of patients with only one vascular lesion; (3)In each type of aortic classification, the conventional technique (surgical 1) was the main surgical (79.67%), and the exchange technique (surgical 3) was the least used (5.09%). (4)Long-term follow-up results showed that the incidence of adverse events in 3 or more vascular stenosis was higher; the results of inter-group comparison showed that the incidence of adverse events in the drug group was 26.7% at 3 months after surgical, which was higher than 8.3% in the surgical group, while at 12 months after surgical, the incidence of adverse events in the drug group was 58.3% in the drug group, which was higher than 23.3% in the surgical group. Conclusion: (1) The more the number of vascular stenosis, the longer the surgical time; (2) Aortic classification is closely related to the type of operation adopted by the patients. No matter which type, the patients are mainly treated with conventional technique (surgical 1). (3)No matter what kind of treatment, the main adverse event of ischemic cerebrovascular disease is transient ischemic attack (TIA).
JIANG Bo
,
LIU Yaohua
,
LIU Lifeng
,
SUN Yali
,
LI Liang
,
ZHANG Baifeng
,
CONG Wei
,
CAI Zhiping
. Observation on the effect of drugs and different interventional procedures in the treatment of ischemic cerebrovascular disease[J]. Journal of Baotou Medical College, 2025
, 41(9)
: 71
-77
.
DOI: 10.16833/j.cnki.jbmc.2025.09.012
[1] 中国营养学会肥胖防控学会, 中国营养学会临床营养分会, 中华预防医学会行为健康学分会, 等.中国居民肥胖防治专家共识[J].西安交通大学学报(医学版), 2022, 43(4):619-631.
[2] 《中国卒中中心报告2022》编写组, 王陇德.《中国卒中中心报告2022》概要[J].中国脑血管病杂志, 2024, 21(8):565-576.
[3] 中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组.中国脑血管疾病分类2015[J].中华神经科杂志, 2017, 50(3): 168
[4] 刘国晶.缺血性脑血管疾病介入支架治疗的临床疗效观察[J].中国药物与临床, 2020, 20(8):1334-1335.
[5] 魏列君, 赵丽丽.介入支架治疗缺血性脑血管疾病的安全性分析[J].智慧健康, 2023, 9(9):133-136, 146.
[6] Caunca MR, Del Brutto V, Gardener H, et al.Cerebral Microbleeds, Vascular Risk Factors, and Magnetic Resonance Imaging Markers:The Northern Manhattan Study[J].J Am Heart Assoc, 2016, 5(9):e003477.
[7] 徐大飞, 楚兰.缺血性脑卒中患者合并脑微出血的危险因素分析[J].中国神经免疫学和神经病学杂志, 2020, 27(2):143-146.
[8] Lee JS, Ko K, Oh JH, et al. Cerebral Microbleeds, Hypertension, and Intracerebral Hemorrhage in Cerebral Autosomal-Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy[J]. Front Neurol, 2017, 8:1-6.
[9] 王素青, 黄生炫, 杨帆.尼莫地平术中灌洗对颅内动脉瘤术后脑血管痉挛的影响[J].中国医药, 2023, 18(3):376-380.
[10] 马林, 方淳, 封灏, 等.症状性颅内大动脉亚急性及慢性闭塞血管内再通治疗的初步经验[J].中华神经外科杂志, 2019, 35(2):166-171.
[11] 冯陆, 韩凯, 赵峻波.介入手术治疗脑供血动脉狭窄的效果探讨[J].临床医学工程, 2023, 30(7):951-952.
[12] 杨杰, 翟海燕.血管内神经介入治疗颈动脉狭窄合并短暂性脑缺血的临床效果[J].临床医学研究与实践, 2022, 7(29):75-78.
[13] 王廉, 吕美萱, 许高权, 等.缺血性脑血管病患者脑血管支架植入手术治疗的有效性及对患者并发症发生的影响[J].中国现代医生, 2021, 59(26):78-81.
[14] 代晓晓.血管内支架介入在缺血性脑卒中治疗中的效果观察及对神经功能的影响[J].中西医结合心血管病电子杂志, 2021, 9(11):29-31.
[15] Luo JC, Wang T, Yang K, et al.Endovascular therapy versus medical treatment for symptomatic intracranial artery stenosis[J].Cochrane Database Syst Rev, 2023, 54(8):395-396.
